Growth Metrics

Jazz Pharmaceuticals (JAZZ) Total Liabilities (2016 - 2025)

Jazz Pharmaceuticals has reported Total Liabilities over the past 16 years, most recently at $7.3 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $7.3 billion for Q4 2025, down 7.3% from a year ago — trailing twelve months through Dec 2025 was $7.3 billion (down 7.3% YoY), and the annual figure for FY2025 was $7.3 billion, down 7.3%.
  • Total Liabilities for Q4 2025 was $7.3 billion at Jazz Pharmaceuticals, down from $7.4 billion in the prior quarter.
  • Over the last five years, Total Liabilities for JAZZ hit a ceiling of $9.1 billion in Q2 2021 and a floor of $3.0 billion in Q1 2021.
  • Median Total Liabilities over the past 5 years was $7.7 billion (2023), compared with a mean of $7.6 billion.
  • Biggest five-year swings in Total Liabilities: surged 210.51% in 2021 and later dropped 11.92% in 2022.
  • Jazz Pharmaceuticals' Total Liabilities stood at $8.3 billion in 2021, then fell by 7.01% to $7.7 billion in 2022, then fell by 1.2% to $7.7 billion in 2023, then grew by 3.42% to $7.9 billion in 2024, then fell by 7.3% to $7.3 billion in 2025.
  • The last three reported values for Total Liabilities were $7.3 billion (Q4 2025), $7.4 billion (Q3 2025), and $7.2 billion (Q2 2025) per Business Quant data.